

## Datasheet: MCA1258SBV790

**BATCH NUMBER 100005592**

<b>Description:</b>	RAT ANTI MOUSE CD45R:StarBright Violet 790
<b>Specificity:</b>	CD45R
<b>Other names:</b>	B220, LY-5
<b>Format:</b>	StarBright Violet 790
<b>Product Type:</b>	Monoclonal Antibody
<b>Clone:</b>	RA3-6B2
<b>Isotype:</b>	IgG2a
<b>Quantity:</b>	100 TESTS/0.5ml

### Product Details

#### Applications

This product has been reported to work in the following applications. This information is derived from testing within our laboratories, peer-reviewed publications or personal communications from the originators. Please refer to references indicated for further information. For general protocol recommendations, please visit [www.bio-rad-antibodies.com/protocols](http://www.bio-rad-antibodies.com/protocols).

	Yes	No	Not Determined	Suggested Dilution
Flow Cytometry	▪			Neat

Where this product has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the product for use in their own system using appropriate negative/positive controls.

#### Target Species

Mouse

#### Species Cross Reactivity

Reacts with: Human, Cat

**N.B.** Antibody reactivity and working conditions may vary between species. Cross reactivity is derived from testing within our laboratories, peer-reviewed publications or personal communications from the originators. Please refer to references indicated for further information.

#### Product Form

Purified IgG conjugated to StarBright Violet 790 - liquid

Max Ex/Em	Fluorophore	Excitation Max (nm)	Emission Max (nm)
	StarBright Violet 790	401	782

#### Preparation

Purified IgG prepared by affinity chromatography on Protein G from tissue culture supernatant

<b>Buffer Solution</b>	Phosphate buffered saline
<b>Preservative Stabilisers</b>	0.09% Sodium Azide (NaN <sub>3</sub> ) 1% Bovine Serum Albumin 0.1% Pluronic F68 0.1% PEG 3350 0.05% Tween 20
<b>Immunogen</b>	Murine leukemia-induced pre-B tumor cells (RAW112)
<b>External Database Links</b>	<b>UniProt:</b> <a href="#">P06800</a> <a href="#">Related reagents</a>  <b>Entrez Gene:</b> <a href="#">19264</a> Ptprc <a href="#">Related reagents</a>
<b>Synonyms</b>	Ly-5
<b>Fusion Partners</b>	Spleen cells from immunized Lewis rats were fused with cells of the rat S194/5 XX0.BU-1 myeloma cell line
<b>Specificity</b>	<b>Rat anti Mouse CD45R antibody, clone RA3-6B2</b> recognizes murine CD45R, a form of the CD45 antigen expressed by B cells and lytically active subsets of NK cells and non-MHC restricted CTL's. Rat anti Mouse CD45R antibody, clone RA3-6B2 immunoprecipitates the high molecular weight form of CD45 (220 kDa).  Rat anti Mouse CD45R antibody, clone RA3-6B2 is suitable for plp fixed paraffin embedded tissues ( <a href="#">Whiteland et al.1995</a> ).
<b>Flow Cytometry</b>	Use 5ul of the suggested working dilution to label 10 <sup>6</sup> cells in 100ul. Best practices suggest a 5 minutes centrifugation at 6,000g prior to sample application.
<b>References</b>	<ol style="list-style-type: none"> <li>1. Coffman, R.L. (1982) Surface antigen expression and immunoglobulin gene rearrangement during mouse pre-B cell development. <a href="#">Immunol Rev. 69: 5-23.</a></li> <li>2. Rosmalen, J.G. <i>et al.</i> (2000) Subsets of macrophages and dendritic cells in nonobese diabetic mouse pancreatic inflammatory infiltrates: correlation with the development of diabetes. <a href="#">Lab Invest. 80 (1): 23-30.</a></li> <li>3. Whiteland, J.L. <i>et al.</i> (1995) Immunohistochemical detection of T-cell subsets and other leukocytes in paraffin-embedded rat and mouse tissues with monoclonal antibodies. <a href="#">J Histochem Cytochem. 43 (3): 313-20.</a></li> <li>4. Spangrude, G.J. <i>et al.</i> (1988) Purification and characterization of mouse hematopoietic stem cells. <a href="#">Science. 241: 58-62.</a></li> <li>5. Spangrude, G.J. <i>et al.</i> (1988) Two rare populations of mouse Thy-1lo bone marrow cells repopulate the thymus. <a href="#">J Exp Med. 167 (5): 1671-83.</a></li> <li>6. Holmes, K.L. <i>et al.</i> (1986) Analysis of neoplasms induced by Cas-Br-M MuLV tumor extracts. <a href="#">J Immunol. 137 (2): 679-88.</a></li> <li>7. Ankeny, D.P. <i>et al.</i> (2009) B cells produce pathogenic antibodies and impair recovery</li> </ol>

- after spinal cord injury in mice. [J Clin Invest. 119: 2990-9.](#)
8. Lundqvist, J. *et al.* (2010) Concomitant infection decreases the malaria burden but escalates relapsing fever borreliosis. [Infect Immun. 78 \(5\): 1924-30.](#)
  9. Herrmann, I. *et al.* (2006) Streptococcus pneumoniae Infection aggravates experimental autoimmune encephalomyelitis via Toll-like receptor 2. [Infect Immun. 74: 4841-8.](#)
  10. Kleiter, I. *et al.* (2010) Smad7 in T cells drives T helper 1 responses in multiple sclerosis and experimental autoimmune encephalomyelitis. [Brain. 133: 1067-81.](#)
  11. Lacroix-Lamande, S. *et al.* (2009) Neonate intestinal immune response to CpG oligodeoxynucleotide stimulation. [PLoS One. 4: e8291.](#)
  12. Bertilaccio, M.T. *et al.* (2011) Lack of TIR8/SIGIRR triggers progression of chronic lymphocytic leukemia in mouse models. [Blood. 118: 660-9.](#)
  13. Gengozian, N. *et al.* (2005) Characterization of a monoclonal antibody identifying a CD45RA antigen on feline leukocytes. [Vet Immunol Immunopathol. 108: 253-64.](#)
  14. Giuriato, S. *et al.* (2010) Conditional TPM3-ALK and NPM-ALK transgenic mice develop reversible ALK-positive early B-cell lymphoma/leukemia. [Blood. 115: 4061-70.](#)
  15. Hawke, S. *et al.* (1998) Long-term persistence of activated cytotoxic T lymphocytes after viral infection of the central nervous system. [J Exp Med. 187: 1575-82.](#)
  16. Nakaya, T. *et al.* (2010) Critical role of Pcid2 in B cell survival through the regulation of MAD2 expression. [J Immunol. 185: 5180-7.](#)
  17. Perry, M.J. *et al.* (2000) Effects of high-dose estrogen on murine hematopoietic bone marrow precede those on osteogenesis. [Am J Physiol Endocrinol Metab. 279: E1159-65.](#)
  18. Gibson-Corley, K.N. *et al.* (2016) A method for histopathological study of the multifocal nature of spinal cord lesions in murine experimental autoimmune encephalomyelitis. [PeerJ. 4: e1600.](#)
  19. Soejima, M. *et al.* (2011) Role of innate immunity in a murine model of histidyl-transfer RNA synthetase (Jo-1)-mediated myositis. [Arthritis Rheum. 63: 479-87.](#)
  20. Stevenson, P.G. *et al.* (2002) Uncoupling of virus-induced inflammation and anti-viral immunity in the brain parenchyma. [J Gen Virol. 83: 1735-43.](#)
  21. Fanning, S. *et al.* (2012) Bifidobacterial surface-exopolysaccharide facilitates commensal-host interaction through immune modulation and pathogen protection. [Proc Natl Acad Sci U S A. 109 \(6\): 2108-13.](#)
  22. Ruf, M.T. *et al.* (2012) Chemotherapy-Associated Changes of Histopathological Features of Mycobacterium ulcerans Lesions in a Buruli Ulcer Mouse Model. [Antimicrob Agents Chemother. 56: 687-96.](#)
  23. Carpenter, R.S. *et al.* (2015) Traumatic spinal cord injury in mice with human immune systems. [Exp Neurol. 271: 432-44.](#)
  24. Lastrucci, C. *et al.* (2015) Molecular and cellular profiles of the resolution phase in a damage-associated molecular pattern (DAMP)-mediated peritonitis model and revelation of leukocyte persistence in peritoneal tissues. [FASEB J. 29 \(5\): 1914-29.](#)
  25. Thiele, L.S.N. *et al.* (2020) Functional relevance of the multi-drug transporter abcg2 on teriflunomide therapy in an animal model of multiple sclerosis. [J Neuroinflammation. 17 \(1\): 9.](#)
  26. Jaensch, S. *et al.* (2022) Clinicopathologic and immunophenotypic features in dogs with presumptive large granular lymphocyte leukaemia [Aus Vet J. Aug 12 \[Epub ahead of print\].](#)

---

**Storage**

Store at +4°C. DO NOT FREEZE.

This product should be stored undiluted.

---

<b>Guarantee</b>	12 months from date of despatch
------------------	---------------------------------

---

<b>Acknowledgements</b>	This product is covered by U.S. Patent No. 10,150,841 and related U.S. and foreign counterparts
-------------------------	---

---

<b>Health And Safety Information</b>	Material Safety Datasheet documentation #20471 available at: <a href="https://www.bio-rad-antibodies.com/SDS/MCA1258SBV790">https://www.bio-rad-antibodies.com/SDS/MCA1258SBV790</a> 20471
--------------------------------------	--

---

<b>Regulatory</b>	For research purposes only
-------------------	----------------------------

---

## Related Products

### Recommended Useful Reagents

[MOUSE SEROBLOCK FcR \(BUF041A\)](#)

[MOUSE SEROBLOCK FcR \(BUF041B\)](#)

<b>North &amp; South America</b>	Tel: +1 800 265 7376 Fax: +1 919 878 3751 Email: <a href="mailto:antibody_sales_us@bio-rad.com">antibody_sales_us@bio-rad.com</a>	<b>Worldwide</b>	Tel: +44 (0)1865 852 700 Fax: +44 (0)1865 852 739 Email: <a href="mailto:antibody_sales_uk@bio-rad.com">antibody_sales_uk@bio-rad.com</a>	<b>Europe</b>	Tel: +49 (0) 89 8090 95 21 Fax: +49 (0) 89 8090 95 50 Email: <a href="mailto:antibody_sales_de@bio-rad.com">antibody_sales_de@bio-rad.com</a>
----------------------------------	---	------------------	---	---------------	---

To find a batch/lot specific datasheet for this product, please use our online search tool at: [bio-rad-antibodies.com/datasheets](https://www.bio-rad-antibodies.com/datasheets)  
'M387266:210621'

Printed on 28 Mar 2025

---

© 2025 Bio-Rad Laboratories Inc | [Legal](#) | [Imprint](#)